NCT05298020

Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer

A Single-arm Phase II Study of Envafolimab Combined With Endostar and Nab-paclitaxel Plus Gemcitabine for First-line Treatment of Advanced Pancreatic Cancer

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: The Affiliated Hospital of Xuzhou Medical University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a single-arm, open-label, exploratory study to evaluate efficacy and safety of envafolimab combined with endostar and nab-paclitaxel plus gemcitabine for first-line treatment of advanced pancreatic cancer.

Detailed description

This study is a prospective, open-label, single-arm, exploratory clinical study. Recruited 20 subjects who met the inclusion criteria and received Endostar+Envofolimab+Nab-paclitaxel/Gemcitabine (AG regimen) chemotherapy according to the study plan. Treatment duration and dose can be adjusted according to patient tolerance until disease progression or intolerable toxicity, or other conditions determined by the investigator. During the trial, the efficacy indicators and safety indicators were observed.

Conditions

• Advanced Pancreatic Cancer

Interventions

Type	Name	Description
DRUG	Envafolimab	400mg,sc,d1,Q4W
DRUG	Endostar	210mg，CIV72h，d1-3，Q4W
DRUG	Nab paclitaxel	125mg/m2,iv,d1,d8,Q4W
DRUG	Gemcitabine	1000mg/m2, iv,d1,d8，Q4W

Timeline

• Start date: 2022-04-01
• Primary completion: 2022-12-01
• Completion: 2023-04-01
• First posted: 2022-03-28
• Last updated: 2022-03-28

Locations

1 site across 1 country: China